Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongkun Sun

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue SarcomaYihebali Chi, Zhiwei Fang, Xiaonan Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.
Liver Cancer|June 23, 2025
Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular CarcinomaXinyu Bi, Yinying Lu, Bo Chen, et al.
Frontiers in Immunology|August 20, 2025
Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patientsYirui Zhai, Yefan Zhang, Fan Wu, et al.
Cancer Medicine|April 11, 2026
Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single CenterLingxia Xin, Zhiyu Li, Yirui Zhai, et al.
The Oncologist|June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)Yihebali Chi, Yongqian Shu, Yi Ba, et al.
Innovation (Cambridge (Mass.))|July 9, 2026
Chinese consensus on first-line precision therapy for advanced gastric cancerXiaotian Zhang, Weiqi Sheng, Tong Xie, et al.
Liver Cancer|August 11, 2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert StatementsYongkun Sun, Wen Zhang, Xinyu Bi, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 17, 2021
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter surveyHong Zhao, Aiping Zhou, Jianguo Zhou, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue SarcomaYihebali Chi, Zhiwei Fang, Xiaonan Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.
Liver Cancer|June 23, 2025
Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular CarcinomaXinyu Bi, Yinying Lu, Bo Chen, et al.
Frontiers in Immunology|August 20, 2025
Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patientsYirui Zhai, Yefan Zhang, Fan Wu, et al.
Cancer Medicine|April 11, 2026
Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single CenterLingxia Xin, Zhiyu Li, Yirui Zhai, et al.
The Oncologist|June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)Yihebali Chi, Yongqian Shu, Yi Ba, et al.
Innovation (Cambridge (Mass.))|July 9, 2026
Chinese consensus on first-line precision therapy for advanced gastric cancerXiaotian Zhang, Weiqi Sheng, Tong Xie, et al.
Liver Cancer|August 11, 2022
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert StatementsYongkun Sun, Wen Zhang, Xinyu Bi, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 17, 2021
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter surveyHong Zhao, Aiping Zhou, Jianguo Zhou, et al.
Pageof 8